Related Experiment Video
Updated: Aug 30, 2026
Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population
Published on: January 31, 2025
Monitoring response to osteoporosis therapy with alendronate by a multisite ultrasound device: a prospective study
Mordechai Weiss1, Maya Koren-Michowitz, Elena Segal
1Endocrine Institute, Assaf Harofeh Medical Center, Zerifin, Israel.
Background:
Osteoporotic fractures are a major health problem among postmenopausal women. A significant proportion of subjects with low bone density are currently undiagnosed. Peripheral devices can be used for osteoporosis diagnosis, but their role in long-term monitoring of skeletal changes is unclear. The current study evaluated the ability of quantitative ultrasound (QUS) measurements to follow osteoporotic subjects treated with alendronate.
Methods:
QUS measurements were done with Sunlight Omnisense (Omnisense, Sunlight Medical Ltd., Tel Aviv, Israel), which determines the bone speed of sound (SOS) in several skeletal sites. Postmenopausal women with T-scores of -2 or less at one site were recruited and treated with alendronate for at least 1 yr. Follow-up was done with QUS and dual-energy X-ray absorptiometry (DXA) (Lunar DPX scanner, Madison, WI, USA) measurements.
Results:
After 12 mo, bone mineral density (BMD) increased significantly at the lumbar spine (LS) (0.34 +/- 0.08 T-score, p = 0.0001 with 95% CI [0.19, 0.49]) and QUS at the tibia (TIB) (0.21 +/- 0.09 T-score, p = 0.02 with 95% CI [0.03, 0.39]). After 12 mo, a significant increase in mean T-scores was demonstrated in all sites assessed according to baseline T-score of -2 or less.
Conclusions:
Peripheral QUS measurement may be considered for follow-up on skeletal changes in response to alendronate treatment.
